Q-omics provides the consensus-scored PKIB profile across patient tissues and cancer cell-line models. PKIB expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PKIB is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, PKIB protein abundance shows 17,607 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, COAD, and GBM as cancer lineages where PKIB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PKIB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PKIB survival associations across molecular data types. PKIB RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PKIB RNA expression–survival associations across cancer types. High PKIB expression shows unfavorable associations in LUAD, MESO and LGG, but favorable associations in HNSC, BRCA and READ. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for PKIB RNA expression.
This table summarizes PKIB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PKIB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PKIB shows lower tumor expression in COAD and higher tumor expression in KIRC, LUAD, KIRP, BLCA and BRCA. The COAD box plot shows higher PKIB RNA expression in normal versus tumor tissue (log2 FC = −4.279, t-test p < 0.001).
This table shows molecular features associated with PKIB in patient tissues and cancer cell lines. In patient samples, PKIB shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PKIB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BREAST.
